Dr. Lal Path Labs Ltd. — Updates, 30-01-2025: Press Release

Dr. Lal PathLabs Limited reported a revenue increase of 10.7% to Rs 597 Cr for the quarter ended December 31, 2024. EBITDA rose by 9.6%, with a margin of 25.8%, while profit after tax (PAT) surged by 19.3%, achieving a margin of 16.4%. The company continues to strengthen its operations with 280 clinical laboratories and over 5,700 Patient Service Centers across India, catering to individual patients, hospitals, and corporate clients. A third interim dividend of Rs 6 per share has been declared for FY25. The company's solid growth metrics and extensive network position it well for continued success. Positive outlook as the focus on expanding services and enhancing operational efficiency persists.